4//SEC Filing
Goddard Glenn 4
Accession 0001209191-21-054315
CIK 0001652130other
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 7:30 PM ET
Size
33.5 KB
Accession
0001209191-21-054315
Insider Transaction Report
Form 4
Goddard Glenn
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-31$14.58/sh+1,817$26,492→ 24,800 total - Sale
Common Stock
2021-08-31$160.22/sh−24,800$3,973,456→ 0 total - Sale
Common Stock
2021-08-30$155.29/sh−1,700$263,993→ 1,696 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-31−22,983→ 41,817 totalExercise: $19.27Exp: 2028-10-31→ Common Stock (22,983 underlying) - Sale
Common Stock
2021-08-30$154.29/sh−1,100$169,719→ 3,396 total - Exercise/Conversion
Common Stock
2021-08-30$19.27/sh+5,200$100,204→ 5,200 total - Sale
Common Stock
2021-08-30$153.22/sh−704$107,867→ 4,496 total - Sale
Common Stock
2021-08-30$156.10/sh−300$46,830→ 1,396 total - Sale
Common Stock
2021-08-30$157.33/sh−496$78,036→ 900 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-31−1,817→ 15,933 totalExercise: $14.58Exp: 2028-12-17→ Common Stock (1,817 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-08-30−5,200→ 64,800 totalExercise: $19.27Exp: 2028-10-31→ Common Stock (5,200 underlying) - Exercise/Conversion
Common Stock
2021-08-31$19.27/sh+22,983$442,882→ 22,983 total
Footnotes (13)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.59, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2021 at each separate price.
- [F11]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 30, 2021.
- [F12]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 63,750 shares as of August 31, 2021.
- [F13]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 11,833 shares as of August 31, 2021.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.75 to $153.62, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.76 to $154.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.805 to $155.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.81 to $156.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.86 to $157.84, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.08 to $158.81, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.31 to $159.79, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.61 to $160.95, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price.
Documents
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001581992
Filing Metadata
- Form type
- 4
- Filed
- Aug 31, 8:00 PM ET
- Accepted
- Sep 1, 7:30 PM ET
- Size
- 33.5 KB